Two Sigma Advisers
GTBP icon

Two Sigma Advisers’s GT Biopharma GTBP Stock Holding History

Two Sigma Advisers’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14
Closed -$30K – 2625
2022
Q2 		$30K Sell
14
-11
-44% -$20.8K ﹤0.01% 2520
2022
Q1 		$53K Sell
25
-135
-84% -$298K ﹤0.01% 2585
2021
Q4 		$366K Buy
160
+92
+135% +$344K ﹤0.01% 2069
2021
Q3 		$344K Buy
68
+48
+240% +$361K ﹤0.01% 2060
2021
Q2 		$231K Buy
+20
New +$208K ﹤0.01% 2230

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Atria Wealth Solutions
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Compagnie Lombard Odier SCmA
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Advisers's GTBP Position: Q3 2022 in Review

Two Sigma Advisers sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 14 shares — an estimated $30K sold.

Two Sigma Advisers first reported a position in GTBP in Q2 2021 and held it in 5 quarters. The position peaked at $366K in Q4 2021. 29 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

  • Two Sigma Advisers reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 14 GT Biopharma shares in Q3 2022, an estimated $30K.
  • Two Sigma Advisers first reported a position in GT Biopharma in Q2 2021 and held it in 5 quarters.
  • Two Sigma Advisers's GT Biopharma position peaked at $366K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.